Mylan Confirms First-to-File Patent Challenge Relating to Actoplus Met® XR Tablets - PR Newswire - sacbee.com

Mylan Inc. (Nasdaq: MYL) today confirmed that the company has been sued by Takeda Pharmaceutical Company, Watson Pharmaceuticals and Andrx Labs in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Pioglitazone Hydrochloride and Extended-release Metformin Hydrochloride tablets, 15 mg/1000 mg and 30 mg/1000 mg.